4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Development of clinical application program for radiotherapy induced cancer risk calculation using Monte Carlo engine in volumetric-modulated arc therapy

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The purpose of this study is to develop a clinical application program that automatically calculates the effect for secondary cancer risk (SCR) of individual patient. The program was designed based on accurate dose calculations using patient computed tomography (CT) data and Monte Carlo engine. Automated patient-specific evaluation program was configured to calculate SCR.

          Methods

          The application program is designed to re-calculate the beam sequence of treatment plan using the Monte Carlo engine and patient CT data, so it is possible to accurately calculate and evaluate scatter and leakage radiation, difficult to calculate in TPS. The Monte Carlo dose calculation system was performed through stoichiometric calibration using patient CT data. The automatic SCR evaluation program in application program created with a MATLAB was set to analyze the results to calculate SCR. The SCR for organ of patient was calculated based on Biological Effects of Ionizing Radiation (BEIR) VII models. The program is designed to sequentially calculate organ equivalent dose (OED), excess absolute risk (EAR), excess relative risk (ERR), and the lifetime attributable risk (LAR) in consideration of 3D dose distribution analysis. In order to confirm the usefulness of the developed clinical application program, the result values from clinical application program were compared with the manual calculation method used in the previous study.

          Results

          The OED values calculated in program were calculated to be at most approximately 13.3% higher than results in TPS. The SCR result calculated by the developed clinical application program showed a maximum difference of 1.24% compared to the result of the conventional manual calculation method. And it was confirmed that EAR, ERR and LAR values can be easily calculated by changing the biological parameters.

          Conclusions

          We have developed a patient-specific SCR evaluation program that can be used conveniently in the clinic. The program consists of a Monte Carlo dose calculation system for accurate calculation of scatter and leakage radiation and a patient-specific automatic SCR evaluation program using 3D dose distribution. The clinical application program that improved the disadvantages of the existing process can be used as an index for evaluating a patient treatment plan.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

          Volumetric modulated arc therapy (VMAT) is a novel radiation technique, which can achieve highly conformal dose distributions with improved target volume coverage and sparing of normal tissues compared with conventional radiotherapy techniques. VMAT also has the potential to offer additional advantages, such as reduced treatment delivery time compared with conventional static field intensity modulated radiotherapy (IMRT). The clinical worldwide use of VMAT is increasing significantly. Currently the majority of published data on VMAT are limited to planning and feasibility studies, although there is emerging clinical outcome data in several tumour sites. This article aims to discuss the current use of VMAT techniques in practice and review the available data from planning and clinical outcome studies in various tumour sites including prostate, pelvis (lower gastrointestinal, gynaecological), head and neck, thoracic, central nervous system, breast and other tumour sites.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The calibration of CT Hounsfield units for radiotherapy treatment planning.

            Computer tomographic (CT) scans are used to correct for tissue inhomogeneities in radiotherapy treatment planning. In order to guarantee a precise treatment, it is important to obtain the relationship between CT Hounsfield units and electron densities (or proton stopping powers for proton radiotherapy), which is the basic input for radiotherapy planning systems which consider tissue heterogeneities. A method is described to determine improved CT calibrations for biological tissue (a stoichiometric calibration) based on measurements using tissue equivalent materials. The precision of this stoichiometric calibration and the more usual tissue substitute calibration is determined by a comparison of calculated proton radiographic images based on these calibrations and measured radiographs of a biological sample. It has been found that the stoichiometric calibration is more precise than the tissue substitute calibration.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Assessing the risk of second malignancies after modern radiotherapy.

              Recent advances in radiotherapy have enabled the use of different types of particles, such as protons and heavy ions, as well as refinements to the treatment of tumours with standard sources (photons). However, the risk of second cancers arising in long-term survivors continues to be a problem. The long-term risks from treatments such as particle therapy have not yet been determined and are unlikely to become apparent for many years. Therefore, there is a need to develop risk assessments based on our current knowledge of radiation-induced carcinogenesis.
                Bookmark

                Author and article information

                Contributors
                mynameiskdj@paik.ac.kr
                shinyj@paik.ac.kr
                jeongsh512@gmail.com
                achinara@paik.ac.kr
                tomato98@gmail.com
                leebr999@gmail.com
                Journal
                Radiat Oncol
                Radiat Oncol
                Radiation Oncology (London, England)
                BioMed Central (London )
                1748-717X
                12 June 2021
                12 June 2021
                2021
                : 16
                : 108
                Affiliations
                [1 ]GRID grid.411627.7, ISNI 0000 0004 0647 4151, Department of Radiation Oncology, , Inje University Sanggye Paik Hospital, ; 1342, Dongil-ro, Nowon-gu, Seoul, Korea
                [2 ]GRID grid.410914.9, ISNI 0000 0004 0628 9810, Proton Therapy Center, , National Cancer Center, ; Goyang, Korea
                [3 ]ARALE Laboratory, Inc, Seoul, Korea
                [4 ]GRID grid.264381.a, ISNI 0000 0001 2181 989X, Department of Radiation Oncology, Samsung Medical Center, School of Medicine, , Sungkyunkwan University, ; 81, Irwon-Ro, Gangnam-Gu, Seoul, 06351 Korea
                Author information
                http://orcid.org/0000-0002-3011-5007
                Article
                1722
                10.1186/s13014-020-01722-0
                8199704
                34118968
                9c7c0143-e0e3-447e-9a01-8d81936c9417
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 4 January 2020
                : 6 December 2020
                Funding
                Funded by: Ministry of Interior and Safety
                Award ID: 2019-MOIS32-024
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2021

                Oncology & Radiotherapy
                tps,monte carlo,secondary cancer risk,clinical application program
                Oncology & Radiotherapy
                tps, monte carlo, secondary cancer risk, clinical application program

                Comments

                Comment on this article